Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: Clinical considerations

被引:57
作者
Ferrandina, Gabriella
Legge, Francesco
Salutari, Vanda
Paglia, Amelia
Testa, Antonia
Scambia, Giovanni
机构
[1] Univ Cattolica Sacro Cuore, Gynaecol Oncol Unit, I-00168 Rome, Italy
[2] Catholic Univ, Dept Oncol, Campobasso, Italy
关键词
ovarian cancer; pattern of recurrence; post-relapse survival; PLATINUM-BASED CHEMOTHERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; STAGE-III; INTRAPERITONEAL CISPLATIN; CYTOREDUCTIVE SURGERY; PACLITAXEL; CARBOPLATIN; CARCINOMA; CYCLOPHOSPHAMIDE;
D O I
10.1016/j.ejca.2006.03.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrence of disease represents a clinical challenge in ovarian cancer patients. The aim of this study was to analyse the distribution and pattern of recurrence and their association with clinical outcome in a large series of ovarian cancer patients. This study was conducted on 328 primary untreated ovarian cancer patients. For each relapse, information on date of clinical/instrumental recurrence, and pattern of disease presentation were retrieved. In stage III-IV cases (n = 270), diffuse abdominal carcinomatosis occurred in 62.1% of cases, while recurrences presented as a single lesion or multiple nodules occurred in 9.9% and 26.7% of cases, respectively. Pattern of recurrence as carcinomatosis was shown to be associated with unfavourable outcome even when stratified according to platinum free interval (PFI) duration. In multivariate analysis, pattern of recurrence and PFI duration retained an independent prognostic role for post-relapse survival. Duration of PFI and type of recurrence may independently influence post-relapse survival in ovarian cancer patients. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2296 / 2302
页数:7
相关论文
共 32 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[3]  
Berkenblit A, 2005, J REPROD MED, V50, P426
[4]   Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? [J].
Cannistra, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1158-1160
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer [J].
D'Agostino, G ;
Amant, F ;
Berteloot, P ;
Scambia, G ;
Vergote, I .
GYNECOLOGIC ONCOLOGY, 2003, 88 (03) :266-269
[7]   Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel - The Memorial Sloan-Kettering Cancer Center experience [J].
Dizon, DS ;
Dupont, J ;
Anderson, S ;
Sabbatini, P ;
Hummer, A ;
Aghajanian, C ;
Spriggs, D .
GYNECOLOGIC ONCOLOGY, 2003, 91 (03) :584-590
[8]   Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients [J].
Eisenhauer, EA ;
Vermorken, JB ;
vanGlabbeke, M .
ANNALS OF ONCOLOGY, 1997, 8 (10) :963-968
[9]  
EISENHAUER EA, 1999, ANN ONCOL S1, V10, pS9, DOI DOI 10.1023/A:1008343015697
[10]   Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study [J].
Eisenkop, SM ;
Spirtos, NM ;
Friedman, RL ;
Lin, WCM ;
Pisani, AL ;
Perticucci, S .
GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :390-396